Bowel cancer is currently the second largest cause of cancer deaths in Australia with over 250 new cases diagnosed every week. It is estimated 1 in 12 Australians will get bowel cancer by the age of 85.
Bevacizumab is a recombinant humanised monoclonal antibody that selectively binds to and neutralises the biological activity of human vascular endothelial growth factor (VEGF). It has recently been placed on the PBS for treating advanced bowel cancer.
The complete RGH Bulletin is available: Bevacizumab for Bowel Cancer (121)
The 2009 RGH E-Bulletins are archived by topic here.
A joint initiative of the Patient Services Section and the Drug and Therapeutics Information Service of the Pharmacy Department, Repatriation General Hospital, Daw Park, South Australia. The RGH Pharmacy E-Bulletin is distributed in electronic format on a weekly basis, and aims to present concise, factual information on issues of current interest in therapeutics, drug safety and cost-effective use of medications.
Editor: Assoc. Prof. Chris Alderman, University of South Australia – Director of Pharmacy, RGH © Pharmacy Department, Repatriation General Hospital, Daw Park, South Australia 5041.
If you like this post and what else you see on the blog please subscribe by RSS feed (the orange button) or by email. Visit my subscription page.
{ 2 trackbacks }
{ 0 comments… add one now }